PTC Therapeutics Q1 total revenue $210M, net loss narrows to $91.6M; pipeline milestones on track

PTC THERAPEUTICS, INC.

2024-Q1 EPS reported -$1.20 revenue$210,118,000

Q1 total revenue $210M (down ~5% YoY); DMD franchise $161M (Translarna $104M, Emflaza $57M).
GAAP net loss $91.6M, improved from $139M loss in Q1 2023; cash $884.8M.
Submitted MAA for sepiapterin (PKU) and BLA for Upstaza (AADC deficiency) in March 2024.
Plans to resubmit Translarna NDA mid-2024; PIVOT-HD (PTC518) interim data in Q2 2024.
Reaffirmed FY2024 total revenue guidance $600-680M; GAAP R&D/SG&A $740-835M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2024 results: revenue $210.1 million, net income $91.6 million. Guidance reaffirmed.

Period: the first quarter ending March 31, 2024
Revenue: $210.1 million
Net income: $91.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin." Key Corporate Updates: ● First quarter 2024 total revenue of $210 million ● First quarter 2024 revenue for the DMD franchise was $161 million o TranslarnaTM (ataluren) net product revenue was $104 million, driven by new patients in existing geographies

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-005767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.